Lots and lots of folks have been asking about this one — all about a “hidden poison” and a company with a “wonder powder” that the ad says could “starve cancer at its source… save countless lives…” and, of course make us all rich. So what is it? Let’s dig into the clues in the […]
I’ve had several folks writing in about the “Alpha Score” that the Profitable Trading folks are selling in a service called Alpha Trader. This is a technicals-driven service, and I’m no market technician or chart-expert, but they also did tease a specific stock that they say is hitting a good “Alpha Score” … so that, […]
Cancer Care: Where Are We and Where Are We Headed?[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
Newsletter ads always sound a little familiar — the same cabal of copywriters are putting together most of these spiels, and they all copy from each other when some new “hook” is found that seems to work to reel in new subscribers. But sometimes it’s a stronger feeling of deja vu than others… and that’s […]
Annual ReviewAll of you, dear Irregulars, know that Stock Gumshoe is not a “tip sheet,” and I don’t operate a portfolio for other people to emulate or copy, or even attempt to track the stocks we cover as if they were a portfolio of buys and sells with consistent trading advice… but I do keep a […]
Introducing: Psychiatry Simplified[ed. note: This is an introductory piece from longtime reader Peter Tilton, who has proposed writing a regular column for Stock Gumshoe readers about psychiatry. Not an investing topic (though the behavior of many of us in the markets may well be something that's in need of a diagnosis), but we thought you might find […]
Apple is my largest personal equity holding, and that makes me a little bit worried again now about short-term jumpiness — it’s not an expensive stock, to be sure, but it is huge and often trades with wild volatility unbecoming a megacap dividend growth stock… … and, perhaps more worrisome, I’ve had my first post-Steve-Jobs […]
Man, I’m starting to have trouble keeping up with all this. The folks at the Palm Beach Letter are so enamored of their “outside the stock market” investment idea that they change the name of it every few months. Whether they’re just testing out which term most appeals to potential subscribers, or because they’re ardently […]
This pitch comes in from Alex Koyfman as an ad for his Penny Stock Millionaire, which has demonstrated a delight with tiny little medical technology stocks — so we’ll warn you up front that there’s every chance that this is a sub-$100 million company that could easily be jolted higher or lower with just a […]
FYI, for those Irregulars who might be interested, the Friday File will be delayed this week. At this time of year I take a look at all of the investments I’ve suggested for or written about for the Irregulars, and all the stocks I own personally, and try to briefly update my opinion and assessment […]